Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Rombach, Saskia M ^a   Aerts, Johannes M F G ^a   Poorthuis, Ben J H M ^a   Groener, Johanna E M ^a   Donker Koopman, Wilma ^a   Hendriks, Erik ^a   Mirzaian, Mina ^a   Kuiper, Sijmen ^a   Wijburg, Frits A ^a   Hollak, Carla E M ^a   Linthorst, Gabor E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; DRUG ANTIBODY; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; LYMPHOCYTE ANTIGEN; SPHINGOSINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROSPRAY MASS SPECTROMETRY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE MASS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PLASMA CLEARANCE; PROGNOSIS; SERODIAGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; URINALYSIS; WHITE MATTER LESION;

ADULT; ALPHA-GALACTOSIDASE; ANTIBODIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLOBOSIDES; GLYCOLIPIDS; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPHINGOLIPIDS; TANDEM MASS SPECTROMETRY; TIME; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES;

EID: 84867668582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047805     Document Type: Article

References (29)

1. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, et al. (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (7): 2102-11.
2. Vedder AC, Linthorst GE, van Breemen MJ, Groener JEM, Bemelman FJ, et al. (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30(1): 68-78.
3. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 345(1): 9-16.
4. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21): 2743-2749.
5. Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG, (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4): 1589-1595.
6. Bénichou B, Goyal S, Sung C, Norfleet AM, Obrien F, (2009) A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 96(1): 4-12.
7. Hollak CEM, Linthorst GE, (2009) Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Mol Genet Metab. 96(1): 1-3.
8. Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, et al. (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 94(3): 319-325.
9. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci 105(8): 2812-2817.
10. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, et al. (2010) Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease. BBA- Molecular Basis of Disease. 9: 1-8.
11. Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, et al. (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26(6): 1797-802.
12. van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, et al. (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812(1): 70-76.
13. Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, et al. (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 31 6(1): 69.
14. Vedder AC, Linthorst GE, Houge G, Groener JEM, Ormel EE, et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2(7): e598.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6): 461-470.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57(6): 450-458.
17. Groener JEM, Poorthuis BJHM, Kuiper S, Helmond MTJ, Hollak CEM, et al. (2007) HPLC for Simultaneous Quantification of Total Ceramide, Glucosylceramide, and Ceramide Trihexoside Concentrations in Plasma. Clin Chem. 53(4): 742-747.
18. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37(8): 911-917.
19. Young E, Mills K, Morris P, Vellodi A, Lee P et al. (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 94(447):51-4.
20. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F, (2006) The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem. 4(4): 289-297.
21. Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, et al. (2012) Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry registry. Mol Genet Metab 105(3): 443-9.
22. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS, (2009) Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. 360(2): 194-195.
23. Garman RD, Munroe K, Richards SM, (2004) Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol 137(3): 496-502.
24. Lubanda J, Anijalg E, Bzdúch V, Thurberg B, Bénichou B, et al. (2009) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med. 11(4): 256-64.
25. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2): 77-86.
26. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C, (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69(7): 1216-1221.
27. Weideman F, Niemann M, Breunig F, Herrmann S, Beer M, et al. (2009) Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy. Circulation 119(4): 487-488.
28. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 18(5): 1547-1557.
29. Schellekens H, (2008) The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. Clinical Therapeutics. 30Suppl B: S50-1.